Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria
0
조회
0
다운로드
0
인용
0
참고문헌
초록
Dear Editor, Ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (CZA) were recently approved for the treatment of complicated intra-abdominal infections and complicated urinary tract infections (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427534.htm, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435629.htm, both accessed February 24, 2016). To date, only one study has simultaneously evaluated the activities of C/T and CZA in vitro against Pseudomonas aeruginosa, and few studies have evaluated the effects of these antibiotics on multi-drug resistant (MDR) gram-negative bacteria [1-3]. This study aimed to examine the activities of C/T and CZA against β-lactam-resistant Enterobacteriaceae and P. aeruginosa clinical isolates.
Abstract
Dear Editor, Ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (CZA) were recently approved for the treatment of complicated intra-abdominal infections and complicated urinary tract infections (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427534.htm, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435629.htm, both accessed February 24, 2016). To date, only one study has simultaneously evaluated the activities of C/T and CZA in vitro against Pseudomonas aeruginosa, and few studies have evaluated the effects of these antibiotics on multi-drug resistant (MDR) gram-negative bacteria [1-3]. This study aimed to examine the activities of C/T and CZA against β-lactam-resistant Enterobacteriaceae and P. aeruginosa clinical isolates.
참고문헌 (9)
- Estabrook M, "In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum β-lactamases", J Clin Microbiol, 52, pp.4049~4052 (2014)
- Sader HS, "Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013", Antimicrob Agents Chemother, 59, pp.3656~3659 (2015)
- Buehrle DJ, "Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates", Antimicrob Agents Chemother, 60, pp.3227~3231 (2016)
- Doern CD, "Detection of Klebsiella pneumoniae carbapenemase (KPC) production in non-Klebsiella pneumoniae Enterobacteriaceae isolates by use of the Phoenix, Vitek 2, and disk diffusion methods", J Clin Microbiol, 49, pp.1143~1147 (2011)
- "Multiplex real-time PCR detection of Klebsiella pneumoniae carbapenemase (KPC) and New Delhi metallo-β-lactamase (NDM-1)" (2010)[URL]
- Manji R, "Multi-center evaluation of the Vitek® MS system for mass spectrometric identification of non-Enterobacteriaceae Gram-negative bacilli", Eur J Clin Microbiol Infect Dis, 33, pp.337~346 (2014)
- Richter SS, "Identification of Enterobacteriaceae by matrix-assisted laser desorption", ionization time-of-flight mass spectrometry using the Vitek MS system, 2013, pp.32, 1571~1578
- Clinical and Laboratory Standards Institute, "Performance standards for antimicrobial susceptibility testing. 25th Informational supplement, M100-S25", Clinical and Laboratory Standards Institute, ~ (2015)
- Sucher AJ, "Ceftolozane", tazobactam: A new cephalosporin and β-lactamase inhibitor combination, 2015, pp.49, 1046~1056